Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice

Pharmacology

Volumn 73, Issue 1, 2005, Pages 31-40

  Yu, Guo Liang ^a   Wei, Er Qing ^a   Zhang, Shi Hong ^a   Xu, Hui Ming ^a   Chu, Li Sheng ^a   Zhang, Wei Ping ^a   Zhang, Qi ^a   Chen, Zhong ^a   Mei, Ru Huan ^a   Zhao, Meng Hui ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Blood brain barrier; Brain edema; Cerebral ischemia; Leukotriene receptor; Montelukast

Indexed keywords

CYSTEINYL LEUKOTRIENE RECEPTOR 1 ANTAGONIST; EVANS BLUE; MONTELUKAST; NORPHENAZONE; PRANLUKAST; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN EDEMA; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CELL DENSITY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; EXTRAVASATION; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; MULTIPLE DRUG DOSE; NERVE CELL; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ACETATES; ANIMALS; ANTIPYRINE; BLOOD-BRAIN BARRIER; BRAIN; BRAIN EDEMA; BRAIN ISCHEMIA; CHROMONES; DOSE-RESPONSE RELATIONSHIP, DRUG; FREE RADICAL SCAVENGERS; INFARCTION, MIDDLE CEREBRAL ARTERY; LEUKOTRIENE ANTAGONISTS; MICE; NERVOUS SYSTEM; NEUROPROTECTIVE AGENTS; PSYCHOMOTOR PERFORMANCE; QUINOLINES; RECEPTORS, LEUKOTRIENE; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 10844232942     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081072     Document Type: Article

References (33)

1. Mabe H, Nagai H, Suzuka T: Role of brain tissue leukotriene in brain edema following cerebral ischaemia: Effect of a 5-lipoxygenase inhibitor, AA-861. Neurol Res 1990;12:165-168.
2. Rao AM, Hatcher JF, Kindy MS, Dempsey RJ: Arachidonic acid and leukotriene C4: Role in transient cerebral ischemia of gerbils. Neurochem Res 1999;24:1225-1232.
3. Ciceri S, Rabuffetti M, Monopoli A, Nicosia S: Production of leukotrienes in a model of focal cerebral ischemia in the rats. Br J Pharmacol 2001;133:1323-1329.
4. Schuhmann MU, Mokhtarzadeh M, Stichtenoth DO, Skardelly M, Klinge PM, Gutzki FM, Samii M, Brinker T: Temporal profiles of cerebrospinal fluid leukotrienes, brain edema and inflammatory response following experimental brain injury. Neurol Res 2003;25:481-491.
5. 4 and vasogenic edema surrounding brain tumors in humans. Ann Neurol 1986;19:592-595.
6. Whitney LW, Ludwin SK, McFarland HF, Biddison WE: Microarray analysis of gene expression in multiple sclerosis and EAE identifies 5-lipoxygenase as a component of inflammatory lesions. J Neuroimmunol 2001;121:40-48.
7. Qu T, Uz T, Manev H: Inflammatory 5-LOX mRNA and protein are increased in brain of aging rats. Neurobiol Aging 2000;2:647-652.
8. 4 selectively increases blood barrier permeability after focal ischemia in rats. J Cereb Blood Flow Metab 1991;11:638-643.
9. 2 production following different reperfusion periods in rat brain after forebrain ischemia correlated with morphological changes. Prostaglandins Leukot Essent Fatty Acids 1993;49:633-641.
10. Zeng LH, Zhang WP, Wang RD, Wei EQ: Protective effect of ONO-1078, a leukotriene receptor antagonist, on focal cerebral ischemia in mice. Acta Pharm Sin 2001;36:148-150.
11. Zhang WP, Wei EQ, Mei RH, Zhu CY, Zhao MH: Neuroprotective effect of ONO-1078, a leukotriene receptor antagonist, on focal ischemia in rats. Acta Pharmacol Sin 2002;23:871-877.
12. Zhang LH, Wei EQ: Neuroprotective effect of ONO-1078, a leukotriene receptor antagonist, on transient global cerebral ischemia in rats. Acta Pharmacol Sin 2003;24:1241-1247.
13. Zhang SH, Wei EQ, Zhu CY, Chen Z, Zhang SF: Protective effect of ONO-1078, a leukotriene receptor antagonist, on focal cerebral ischemia induced by endothelin-1 in rats. Acta Pharm Sin 2004;39:1-4.
14. 4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 1996;98:528-534.
15. Obata T, Okada Y, Motoishi M, Nakagawa N, Terawaki T, Aishita H: In vitro antagonism of ONO-1078, a newly developed anti-asthma agent, against peptide leukotrienes in isolated guinea pig tissues. Jpn J Pharmacol 1992;60:227-237.
16. Sarau HM, Ames RS, Chambers J, Ellis C, Elshourbagy N, Foley JJ, Schmidt DB, Muccitelli RM, Jenkins O, Murdock PR, Herrity NC, Halsey W, Sathe G, Muir AI, Nuthulaganti P, Dytko GM, Buckley PT, Wilson S, Bergsma DJ, Hay DW: Identification, molecular cloning, expression and characterization of a cysteinyl leukotriene receptor. Mol Pharmacol 1999;56:657-663.
17. 4 in human lung parenchyma. Biochem Pharmacol 2002;63:1537-1546.
18. Watanabe T, Yuki S, Egawa M, Nishi H: Protective Effects of MCI-186 on cerebral ischemia: Possible involvement of free radical scavenging and antioxidant actions. J Pharmacol Exp Ther 1994;268:1597-1604.
19. Kawai H, Nakai H, Suga M, Yuki S, Watanabe T, Saito K: Effect of a novel free radical scavenger, MCI-186, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. J Pharmacol Exp Ther 1997;281:921-927.
20. Ikeda T, Xia YX, Kaneko M, Sameshima H, Ikenoue T: Effect of the free radical scavenger, 3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186), on hypoxia-ischemia-induced brain injury in neonatal rats. Neurosci Lett 2002;329:33-36.
21. Edaravone Acute Infarction Study Group: Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 2003;15:222-229.
22. Longa EZ, Weinstein PR, Carlson S, Cummins R: Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989;20:84-91.
23. Wei EQ, Zhu CY, Xu QQ, Yu YP, Zhu YF, Zheng MZ: An improved quantitative method for evaluating neurological deficits in mice with focal cerebral ischemia. Acta Physiol Sin 2003;55:742-747.
24. Yonemori F, Yamaguchi T, Yamada H, Tamura A: Evaluation of a motor deficit after chronic focal cerebral ischemia in rats. J Cereb Blood Flow Metab 1998;18:1099-1106.
25. Lin TN, He YY Wu G, Khan M, Hsu CY: Effect of brain edema on infarct volume in a focal cerebral ischemia model in rats. Stroke 1993;24:117-121.
26. Belayev L, Busto R, Zhao WH, Ginsberg MD: Quantitative evaluation of blood-brain barrier permeability following middle cerebral occlusion in rats. Brain Res 1996;739:88-96.
27. Heise CE, O'Dowd BF, Figueroa DJ, Sawyer N, Nguyen T, Im DS, Stocco R, Bellefeuille JN, Abramovitz M, Cheng R, Williams DL Jr, Zeng Z, Liu Q, Ma L, Clements MK, Couloms N, Liu Y, Austin CP, George SR, O'Neill GP, Metters KM, Lynch KR, Evans JF: Characterization of the human cysteinyl leukotriene-2 receptor. J Biol Chem 2000;275:30531-30536.
28. Zhang WP, Hu H, Zhang L, Ding W, Yao HT, Chen KD, Sheng WW, Chen Z, Wei EQ: Expression of cysteinyl leukotriene receptor-1 in human traumatic brain injury and brain tumors. Neurosci Lett 2004;363:247-251.
29. 1 receptor. Eur J Biochem 2001;268:2578-2586.
30. 4 and regulation of vascular and inflammatory responses. Am J Pathol 2001;158:3-9.
31. Yrjänheikki J, Tikka T, Keinänen R, Goldsteins G, Chan PH, Koistinaho J: A tetracycline derivative, minocycline, reduced inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA 1999;96:13496-13500.
32. Toomey JR, Valocik RE, Koster PF, Gabriel MA, McVey M, Hart TK, Ohlstein EH, Parsons AA, Barone FC: Inhibition of factor IX(a) is protective in a rat model of thromboembolic stroke. Stroke 2002;33:578-585.
33. Saibara T, Toda K, Wakatsuki A, Ogawa Y, Ono M, Onishi S: Protective effect of 3-methyl-1-phenyl-2-pyrazolin-5-one, a free radical scavenger, on acute toxicity of paraquat in mice. Toxicol Lett 2003;143:51-54.